跳至主要内容
临床试验/NCT03834129
NCT03834129已完成3 期

Interest of Intravenous Dexmedetomidine (Dexdor®) in the Knee Replacement Surgery Performed Under Locoregional Anesthesia: a Randomized, Double Blind, Controlled Clinical Trial

CMC Ambroise Paré1 个研究点 分布在 1 个国家目标入组 94 人开始时间: 2019年5月13日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
94
试验地点
1
主要终点
Evaluate the effect of dexmedetomidine infusion 2 μg/kg in pre-anesthesia and operative room, on duration of postoperative analgesia after a knee arthroplasty performed under locoregional anesthesia.

研究概览

简要总结

Intravenous dexmedetomidine is a drug used in reanimation with sedative, anxiolytic and sympatholytic properties. Recent studies showed useful properties for anaesthesia : decrease of morphine consumption after a various type of surgery, sedative effect on patients under regional anaesthesia, prolongation of central or peripheral regional block. Dose-ranging study for intravenous dexmedetomidine showed that 2 µg/kg is an effective dose to prolong interscalene block. This study aims to determine if intravenous dexmedetomidine at 2 µg/kg allows a longer analgesic duration after a quadri-block (femoral, subgluteal sciatic, obturator and alateral cutaneous nerve blocks) with ropivacaine 0.32% for total knee replacement under regional anaesthesia.

详细描述

This is a prospective, randomized, double-blind controlled trial with two parallel groups. All patients undergoing total knee arthroplasty under regional anaesthesia and sedation will be screened for inclusion in the protocol. In the pre-anaesthesia room, after the implementation of classical monitoring with an oxygen mask and a peripheral venous catheter, all patients will receive an antibioprophylaxy according to SFAR recommendations and injection of 10 mg of IV dexamethasone.

The patients will be then randomized in 2 groups:

  • Dexmedetomidine group (Dex group) : Two administrations of 1 microg/kg of Dexdor® in 250 ml of sodium chloride during 30 min. The first injection will be performed in the pre-anaesthesia unit and the second in the operating room with a free interval of 60 min between the beginning of the 2 injections.
  • Control group : Two administrations of 250 ml of sodium chloride during 30 min according to the same former recommendations.

Under ultrasonography guidance and with in-plan technic, a quadri-block (femoral, sciatic subgluteal, obturator and lateral cutaneous nerve blocks) with a maximum of 225 mg of ropivacaine diluted in 70 ml of sodium chloride (ropivacaine 0.32 %) will be performed. If needed, sedation with 5 µg of sufentanil and 1 to 2 mg of midazolam will be performed before regional anaesthesia.

In the operating room, under close monitoring, the patients will receive a bolus of Ketamine 0.3 mg/kg and a propofol bolus of 0.3 mg/kg followed by a continuous infusion if needed. The total dose of propofol used for sedation, conversion to general anaesthesia or any complications concerning anaesthesia or dexmedetomidine (hypotension, bradycardia, arrhythmia, advance cardiac block) will be collected. Postoperative analgesia will be reached with IV 1 g paracetamol and 100 mg ketoprofen starting during surgery and following in the surgical ward by oral paracetamol 1 g / 6 h and oral ibuprofen 400 mg / 8 h. In post anaesthesia care unit all the patients will have oxycodone titration if pain VRS (verbal rating scale) >3 and oxycodone 10 mg/ 4 h in the surgical ward if pain VRS (verbal rating scale) >3.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 years and older
  • Patients undergoing elective total knee arthroplasty
  • Consent for participation
  • Affiliation to the french social security system
  • For women of child bearing potential without contraception, beta-HCG negative result

排除标准

  • Chronic pain syndrome requiring preoperative morphine use (class 3)
  • Hypersensitivity to dexmedetomidine
  • Allergy to nonsteroidal anti-inflammatory drugs
  • Contraindication for locoregional anesthesia
  • Patient wishing a general anesthesia
  • Weight>100 kg, obstructive sleep apnea syndrome or gastrooesophageal reflux complicating the sedation with spontaneous ventilation
  • Known acute ischemic disease
  • Severe liver failure
  • Uncontrolled low blood pressure
  • Heart rate < 60 bpm
  • Advanced cardiac block (Level 2 or 3) except if pacemaker
  • Pregnant or breastfeeding women
  • Communication difficulties or neuropsychiatric disorder
  • Patients under protection of the adults (guardianship, curators or safeguard of justice)

研究组 & 干预措施

(Dex group) intravenous infusion of dexmedetomidine

Experimental

Pre-anesthetic and per-operative intravenous infusions of dexmedetomidine 1µg/kg in 250ml of sodium chloride 0.9%

干预措施: Dexmedetomidine (Drug)

(Control group) intravenous infusion of physiological serum

Placebo Comparator

Pre-anesthetic and per-operative intravenous infusions of 250ml of sodium chloride 0.9%

干预措施: sodium chloride 0.9% (Drug)

结局指标

主要结局

Evaluate the effect of dexmedetomidine infusion 2 μg/kg in pre-anesthesia and operative room, on duration of postoperative analgesia after a knee arthroplasty performed under locoregional anesthesia.

时间窗: 48 hours

Duration of analgesia defined as the time between the performance of regional anesthesia and the first dose of rescue analgesia with opioides.

次要结局

  • Quadricep mobilization(Days 0, 1 and 2)
  • Maximal postoperative pain.(48 hours)
  • Dose of hypnotic drug during surgery.(4 hours)
  • Incidence of hypotension or bradycardia Events.(48 hours)
  • Postoperative opioids morphine consumption.(48 hours)
  • Ability to walk(Days 0, 1 and 2)
  • Foot elevator muscle mobilization(Days 0, 1 and 2)

研究者

发起方
CMC Ambroise Paré
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Dexmedetomidine Intra Venous Arthroplasty | 临床试验